The government followed the recommendation of the National Institute of Public Health that anyone who received the first dose of AstraZeneca be offered the mRNA vaccine as a second dose.
The use of AstraZeneca is suspended until May 10. There is a need for an explanation for the second dose
The government has set up a committee of experts to investigate the use of vaccines containing viral vectors such as AstraZeneca in Norway. The committee, chaired by Lars Vorland, will present its report on 10 May. Until then, the use of AstraZeneca has been suspended. The vaccines from Pfizer-BioNTech and Moderna are based on another type of technology called mRNA.
- There is a need for an explanation on the administration of dose 2 before the Vorland committee delivers its report. That's why people who have received one dose of AstraZeneca will receive a second dose of Pfizer-BioNTech or Moderna, says Minister of Health and Care Bent Høie.
To ensure equal treatment to those who received the first dose AstraZeneca vaccines, it was decided that the second dose would be an mRNA vaccine
The first to receive AstraZeneca in Norway were vaccinated at week 6, while most were vaccinated at week 8-10. 12 weeks between the first and second doses are recommended.
To ensure equal treatment and predictability for those who receive the first dose of AstraZeneca, it is up to everyone to decide that the second dose will be an mRNA vaccine.
In Norway, around 135 people were vaccinated with AstraZeneca
About 135 people were vaccinated with AstraZeneca in Norway before it was temporarily removed from the Norwegian Covid-000 immunization program due to rare but serious side effects. 19 percent of those vaccinated are healthcare professionals.
Norwegian Institute of Health The public recommends administration of the mRNA vaccine at week 12 to provide protection.
Several countries, including Denmark, Finland, France and Germany, are already offering mRNA vaccine as a second dose to people who received the first dose of AstraZeneca.
